Diazoxide choline controlled release - Soleno Therapeutics

Drug Profile

Diazoxide choline controlled release - Soleno Therapeutics

Alternative Names: DCCR; DCCR - Soleno Therapeutics; Diazoxide choline; Diazoxide choline controlled release

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Essentialis
  • Developer Essentialis; Soleno Therapeutics
  • Class Antihypertensives; Antihypoglycaemics; Benzothiadiazines; Diagnostic agents; Peripheral vasodilators; Small molecules
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Prader-Willi syndrome
  • No development reported Hypertriglyceridaemia
  • Discontinued Hypoglycaemia; Obesity

Most Recent Events

  • 08 Jan 2018 Diazoxide choline controlled release - Essentialis receives Orphan Drug status for Prader-Willi syndrome in European Union
  • 14 Nov 2017 Soleno Therapeutics plans a phase III trial for Prader-Willi syndrome in USA in 2018 (PO) (NCT03440814)
  • 14 Nov 2017 Diazoxide choline controlled-release formulation is still in phase I/II trial for Prader-Willi syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top